Matching the responses noted for the ACA analysis, SRA737 treatment led to clear increases in the number of γH2AX-foci (reflecting likely DSB formation) for the TP53 MUT NSCLC and CRC cells, with consistently lower foci numbers being noted for the corresponding TP53 WT cells (Figure 2). This evidence concerns the gene TP53 and non-small cell lung carcinoma.